Effect of Hibiscus esculentus on blood sugar and lipids of Type 2 diabetic patients

Evaluation the effect of Hibiscus esculentus on blood sugar and lipids of patients with type 2 Diabetes: A double blind clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180609040020N1

Enrollment

Registered

2018-06-15

Start date

2018-07-07

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Type 2 diabetic patients who use powder of Hibiscus esculentus with the dose of 1000 milligrams three times daily before breakfast, lunch, and dinner for 60 days. I

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Having type 2 diabetes at least three months before entering the study Age between 20 and 80 years Hemoglobin A1C more than 7.5 at time of entering the study Using a contraceptive method in women during reproductive age who entered the study

Exclusion criteria

Exclusion criteria: Unwillingness of the patient Having known Immune deficiency Pregnancy and breastfeeding Obeying a diet regimen or especial kind of exercise Using supplements containing Hibiscus esculentus Cardiovascular diseases History of hepatic and renal diseases Uncontrolled thyroid disease History of diabetic ketoacidosis Creatinine more than 2 Using drugs that have an effect on blood sugar level including Corticosteroids and thiazides Known allergy to Hibiscus esculentus plant Manifestation of acute physical problems during the intervention Changing the type of treatment and manifestation of hypoglycemia symptoms Severe Weight loss at least 10 percent during the past 6 months

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: At the beginning of the intervention and at the end of intervention on the day 60. Method of measurement: Blood test.	—

Secondary

Measure	Time frame
Hemoglobin A1C. Timepoint: En At the beginning of the intervention and at the end of intervention on the day 60. Method of measurement: Blood test.;Cholesterol. Timepoint: At the beginning of the intervention and at the end of intervention on the day 60. Method of measurement: Blood Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Hesamzadeh

Sari University of Medical Sciences

a.hesamzadeh@mazums.ac.ir+98 11 3321 9437

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026